切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2016, Vol. 10 ›› Issue (06) : 406 -409. doi: 10.3877/cma.j.issn.1674-0793.2016.06.005

所属专题: 文献

论著

干细胞标记物Lgr5在胃癌组织中的表达及临床意义
黄江龙1,(), 魏波1, 郑宗珩1, 刘健培1, 陈图锋1, 黄勇1, 方佳峰1   
  1. 1. 510630 广州,中山大学附属第三医院胃肠外科
  • 收稿日期:2016-03-05 出版日期:2016-12-01
  • 通信作者: 黄江龙
  • 基金资助:
    广东省科技计划项产学研合作项目(2014B090901066); 广东省自然科学基金-博士启动项目(2015A030310052); 广州市产学研协同创新重大专项项目(2060404); 广东省医学科研基金资助项目(B2013127)

Expression and clinical significance of stem cell marker Lgr5 protein in human gastric carcinoma

Jianglong Huang1,(), Bo Wei1, Zongheng Zheng1, Jianpei Liu1, Tufeng Chen1, Yong Huang1, Jiafeng Fang1   

  1. 1. Department of Gastrointestinal Surgery, the Third Affiliated Hospital of Sun Yat-sen University, GuangZhou 510630, China
  • Received:2016-03-05 Published:2016-12-01
  • Corresponding author: Jianglong Huang
  • About author:
    Corresponding author: Huang Jianglong, Email:
引用本文:

黄江龙, 魏波, 郑宗珩, 刘健培, 陈图锋, 黄勇, 方佳峰. 干细胞标记物Lgr5在胃癌组织中的表达及临床意义[J/OL]. 中华普通外科学文献(电子版), 2016, 10(06): 406-409.

Jianglong Huang, Bo Wei, Zongheng Zheng, Jianpei Liu, Tufeng Chen, Yong Huang, Jiafeng Fang. Expression and clinical significance of stem cell marker Lgr5 protein in human gastric carcinoma[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2016, 10(06): 406-409.

目的

分析干细胞标记物Lgr5(富含亮氨酸重复单位的G蛋白偶联受体5)蛋白在人胃癌组织中的异常表达,并探讨在胃癌肿瘤的发生发展等过程中发挥的作用。

方法

选取2012年1月至2015年6月接受胃癌手术治疗的70例患者,采用免疫组化法分别检测70例胃正常组织、癌旁组织、胃腺癌标本中Lgr5的蛋白表达,并统计学分析其与临床病理指标、患者生存预后的关系。

结果

70例胃癌组织中的Lgr5蛋白阳性表达率(50/70,71.4%)明显高于癌旁组织(35/70,50.0%)、正常组织(21/70,30.0%),差异有统计学意义(χ2=6.738、24.034,P=0.009、0.000);Lgr5蛋白的表达与胃癌患者的性别、年龄及分化程度无明显相关性,与淋巴结节转移、TNM分期密切相关(均P<0.05)。随访胃癌患者66例,其中Lgr5阳性组47例,Lgr5阴性组19例,生存分析两组术后3年生存率差异有统计学意义(χ2=3.929,P=0.047)。

结论

Lgr5蛋白在胃癌发生过程中可能发挥一定作用,它与胃癌的侵袭、转移和预后明显相关,Lgr5的表达检测可作为判断胃癌患者预后的一种手段。

Objective

To investigate the expression and its significance of Lgr5 protein in gastric cancer.

Methods

Lgr5 expression was detected by immunohistochemistry in normal tissues, paracancerous tissues and gastric cancer tissues of 70 patients with gastric cancer treated from January 2012 to June 2015. Clinicopathological information and prognosis data of these 70 patients were analyzed to figure out the role of Lgr5 in gastric cancer.

Results

The expression rate of Lgr5 in tumor tissues (50/70, 71.4%) was significant higher than that in both normal tissues (21/70, 30.0%, χ2=24.034, P=0.000) and paracancerous tissues (35/70, 50.0%, χ2=6.738, P=0.009). Lgr5 expression was significantly correlated with TNM stage and lymph node metastasis. There was no correlation between expression of Lgr5 with age, differentiation, and clinical characteristics in gastric cancer. Kaplan-Meier analysis showed significant difference in 3-year survival rates between groups with and without Lgr5 expression (χ2=3.929, P=0.047).

Conclusions

Expression of Lgr5 in gastric cancer indicates that stem cells may be involved in the pathogenesis of gastric cancer and Lgr5 may play an important role in the development and progression of gastric cancer. Lgr5 expression might be a useful marker of poor prognosis in gastric cancer.

表1 Lgr5蛋白在胃正常组织、癌旁组织、胃腺癌标本中的表达(例)
图1 免疫组织化学方法检测Lgr5在正常胃组织、癌旁组织和胃腺癌组织中的表达(SP法×200)
表2 Lgr5蛋白的表达与胃癌临床病理特征之间的关系(例)
图2 Lgr5蛋白阳性表达及阴性表达的胃癌患者生存曲线
1
Siegel R,Naishadham D,Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
2
Ong BA,Vega KJ,Houchen CW. Intestinal stem cells and the colorectal cancer microenvironment[J]. World J Gastroenterol, 2014, 20(8): 1898-1909.
3
Ribatti D. Cancer stem cells and tumor angiogenesis[J]. Cancer Lett, 2012, 321(1): 13-17.
4
Oliveras-Ferraros C,Vazquez-Martin A,Cuyàs E, et al. Ac-quired resistance to metformin in breast cancer cells triggers tran-scriptome reprogramming toward a degradome-related metastatic stem-like profile[J]. Cell Cycle, 2014, 13(7): 1132-1144.
5
Paldino E,Tesori V,Casalbore P, et al. Tumor initiating cells and chemoresistance: which is the best strategy to target colon cancer stem cells?[J]. Biomed Res Int, 2014, 2014: 859871.
6
Crowder SW,Balikov DA,Hwang YS, et al. Cancer stem cells un-der hypoxia as a chemoresistance factor in breast and brain[J]. Curr Pathobiol Rep, 2014, 2(1): 33-40.
7
Vermeulen L,Morrissey E,van der Heijden M, et al. Defining stem cell dynamics in models of intestinal tumor initiation[J]. Sci-ence, 2013, 342(6161): 995-998.
8
Schmitz V,Barajas M,Wang L, et al. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma[J]. Hepatology, 2001, 34(1): 72-81.
9
Barker N,van Es JH,Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5[J]. Nature, 2007, 449(7165):1003-1007.
10
Barker N,Ridgway RA,van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer[J]. Nature, 2009, 457(7229): 608-611.
11
Barker N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration[J]. Nat Rev Mol Cell Biol, 2014, 15(1): 19-33.
12
Tanese K,Fukuma M,Yamada T, et al. G-protein-coupled recep-tor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation[J]. Am J Pathol, 2008, 173(3): 835-843.
13
Becker L,Huang Q,Mashimo H. Immunostaining of Lgr5, an in-testinal stem cell marker, in normal and premalignant human gastrointestinal tissue[J]. ScientificWorldJournal, 2008, 8: 1168-1176.
14
Hartgrink HH,Jansen EP,van Grieken NC, et al. Gastric cancer[J]. Lancet, 2009, 374(9688): 477-490.
15
Yamanoi K,Fukuma M,Uchida H, et al. Overexpression of leu-cine-rich repeat-containing G protein-coupled receptor 5 in gas-tric cancer[J]. Pathol Int, 2013, 63(1): 13-19.
16
Bu Z,Zheng Z,Zhang L, et al. LGR5 is a promising biomarker for patients with stage Ⅰand Ⅱ gastric cancer[J]. Chin J Cancer Res, 2013, 25(1): 79-89.
17
刘元华,樊祥山,恽艳.应用组织芯片技术检测胃癌组织中Lgr5和CD44的表达[J].中国肿瘤外科杂志, 2015, 7(6): 341-345.
[1] 宋勤琴, 李双汝, 李林, 杜鹃, 刘继松. 间充质干细胞源性外泌体在改善病理性瘢痕中作用的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 550-553.
[2] 安杰, 牛云峰, 刘伟. LINC00520 通过miR-519b-3p/HIF1A 轴促进胃癌的侵袭转移[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 430-436.
[3] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[4] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[5] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[6] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[7] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[8] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[9] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[10] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[11] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[12] 刘海旺, 施海, 尚利峰. 不同吻合器在腹腔镜远端胃癌根治术Roux-en-Y式吻合中的应用对比[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 643-646.
[13] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[14] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[15] 张立俊, 孙存杰, 胡春峰, 孟冲, 张辉. MSCT、DCE-MRI 评估术前胃癌TNM 分期的准确性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 519-523.
阅读次数
全文


摘要